Skip to main content
Equibles
JNJ logo

JNJ · Johnson & Johnson · Earnings Call Transcripts & Audio

Track JNJ — free

Use JNJ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JNJ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$270.31 +0.09 (+0.03%)
S&P 500 member Russell 1000 member Dow 30 member Rebalance outlook locked
Market Cap
$641.80B
Shares
2.41B

Johnson & Johnson Earnings Call Transcripts

Quarterly earnings calls for Johnson & Johnson (JNJ), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲6.8% $21.35B $26.03B '23 Q3 23-01-24 ▲7.3% $21.39B $4.05B '23 Q4 23-04-18 ▲2.3% $21.38B $3.25B '24 Q1 23-08-15 ▲4.3% $22.45B $4.69B '24 Q2 23-10-17 ▲5.2% $22.47B $2.69B '24 Q3 24-01-23 ▲2.4% $21.89B $11.00B '25 Q1 24-05-01 ▲5.3% $22.52B $3.43B '24 Q4 24-05-01 ▲5.8% $23.74B $5.54B '25 Q2 24-10-15 ▲6.8% $23.99B $5.15B '25 Q3 25-01-22 ▲9.1% $24.56B $5.12B '25 Q4 25-04-15 ▲9.9% $24.06B $5.24B '26 Q1 25-07-16 LATEST ▲6.6% $25.31B $5.53B '26 Q2 25-10-14
Earnings call
FY27 · Q3
2026-10-13
Johnson & Johnson (JNJ) Q3 2027 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-14
Johnson & Johnson (JNJ) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Johnson & Johnson (JNJ) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY27 · Q2
2026-07-15
Johnson & Johnson (JNJ) Q2 2027 Earnings Call Transcript
Confident tone Icotreke launch momentum Inlexo bladder cancer launch Tremphia / immunology growth
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Johnson & Johnson (JNJ) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-27
Johnson & Johnson (JNJ) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY27 · Q1
2026-04-14
Johnson & Johnson (JNJ) Q1 2027 Earnings Call Transcript
Confident tone Icotride (Iketide/Tremfya) launch in psoriatic disease Inlexo (nadofaragene) bladder cancer launch and J-code Pipeline catalysts and upcoming readouts
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-10
Johnson & Johnson (JNJ) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q4
2026-01-21
Johnson & Johnson (JNJ) Q4 2026 Earnings Call Transcript
Confident tone MedTech product launches 2025 results and 2026 guidance R&D pipeline and approvals
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q2
2025-10-14
Johnson & Johnson (JNJ) Q2 2026 Earnings Call
Revenue
$25.31B
▲ 6.6% YoY
Diluted EPS
$2.27
▼ 0.9% YoY
Gross margin
68.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-07-16
Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript
Confident tone Immunology franchise with ICOTYDE and TREMFYA MedTech and surgery platform Innovative Medicine growth and oncology portfolio
Revenue
$24.06B
▲ 9.9% YoY
Diluted EPS
$2.14
▼ 52.9% YoY
Gross margin
66.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-04-15
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Confident tone 2026 Financial Guidance MedTech Portfolio & New Launches Talc Litigation
Revenue
$24.56B*
▲ 9.1% YoY
Gross margin
67.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-01-22
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Confident tone MedTech performance and portfolio focus Immunology (TREMFYA, icotrokinra) Q3 operational sales growth across portfolio
Revenue
$23.99B
▲ 6.8% YoY
Diluted EPS
$2.12
▲ 91% YoY
Gross margin
69.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2024-10-15
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Confident tone Medtech / Cardiovascular Innovative Medicine / Oncology Growth STELARA Loss of Exclusivity
Revenue
$23.74B
▲ 5.8% YoY
Diluted EPS
$2.29
▲ 18.7% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-05-01
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Confident tone MedTech performance and innovation Innovative Medicine growth and pipeline M&A and capital allocation
Revenue
$22.52B*
▲ 5.3% YoY
Gross margin
68.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q1
2024-05-01
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
Confident tone Diversified business resilience post-STELARA LOE Tremfya IBD launch (UC and Crohn's) Oncology portfolio momentum (DARZALEX, Rybrevant/Lazcluze)
Revenue
$21.89B
▲ 2.4% YoY
Diluted EPS
$4.54
▲ 238.8% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-01-23
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Confident tone Innovative Medicine Growth MedTech and Cardiovascular Expansion Pipeline and Regulatory Approvals
Revenue
$22.47B
▲ 5.2% YoY
Diluted EPS
$1.11
▼ 89.1% YoY
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2023-10-17
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript
Revenue
$22.45B
▲ 4.3% YoY
Diluted EPS
$1.93
▼ 1.5% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-08-15
Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript
Revenue
$21.38B
▲ 2.3% YoY
Diluted EPS
$1.34
Gross margin
69.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-04-18
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
Revenue
$21.39B
▲ 7.3% YoY
Diluted EPS
$1.67
▲ 25.6% YoY
Gross margin
68.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-01-24
Johnson & Johnson (JNJ) Q3 2023 Earnings Call Transcript
Revenue
$21.35B
▲ 6.8% YoY
Diluted EPS
$10.21
▲ 507.7% YoY
Gross margin
69.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2022-11-01
Johnson & Johnson (JNJ) Q2 2023 Earnings Call Transcript
Revenue
$21.52B
▲ 6.5% YoY
Diluted EPS
$1.96
▲ 8.9% YoY
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-07-19
Johnson & Johnson (JNJ) Q1 2023 Earnings Call Transcript
Revenue
$20.89B
▲ 5.3% YoY
Diluted EPS
$-0.03
▼ 101.6% YoY
Gross margin
68.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-04-19
Johnson & Johnson (JNJ) Q4 2022 Earnings Call Transcript
Revenue
$19.94B
▲ 104.1% YoY
Diluted EPS
$1.33
Gross margin
69.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-01-25
Johnson & Johnson (JNJ) Q3 2022 Earnings Call Transcript
Revenue
$20.00B
▼ 14.3% YoY
Diluted EPS
$1.68
▲ 22.6% YoY
Gross margin
69.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2021-10-19
Johnson & Johnson (JNJ) Q2 2022 Earnings Call Transcript
Revenue
$20.21B
▼ 13.3% YoY
Diluted EPS
$1.80
▼ 23.4% YoY
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-07-21
Johnson & Johnson (JNJ) Q1 2022 Earnings Call Transcript
Revenue
$19.84B
▼ 11.1% YoY
Diluted EPS
$1.93
▼ 16.8% YoY
Gross margin
69.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-04-20
Johnson & Johnson (JNJ) Q4 2021 Earnings Call Transcript
Revenue
$9.77B*
▼ 56.5% YoY
Gross margin
84.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-01-26
Johnson & Johnson (JNJ) Q3 2021 Earnings Call Transcript
Revenue
$23.34B
▲ 10.7% YoY
Diluted EPS
$1.37
▲ 3% YoY
Gross margin
68.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2020-10-13
Johnson & Johnson (JNJ) Q2 2021 Earnings Call Transcript
Revenue
$23.31B
▲ 27.1% YoY
Diluted EPS
$2.35
▲ 72.8% YoY
Gross margin
67.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-07-16
Johnson & Johnson (JNJ) Q1 2021 Earnings Call Transcript
Revenue
$22.32B
▲ 7.9% YoY
Diluted EPS
$2.32
▲ 6.9% YoY
Gross margin
68.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-04-14
Johnson & Johnson (JNJ) Q4 2020 Earnings Call Transcript
Revenue
$22.48B*
▲ 8.3% YoY
Gross margin
65.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-01-22
Johnson & Johnson (JNJ) Q3 2020 Earnings Call Transcript
Revenue
$21.08B
▲ 1.7% YoY
Diluted EPS
$1.33
▲ 101.5% YoY
Gross margin
66.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2019-04-30
Johnson & Johnson (JNJ) Q1 2020 Earnings Call Transcript
Revenue
$20.69B
▲ 3.3% YoY
Diluted EPS
$2.17
▲ 56.1% YoY
Gross margin
65.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–34 of 34 earnings calls
Key facts CIK 200406 CUSIP 478160104 13F (30d) 155 filings 78 filers Visit website Investor relations